As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the patient monitoring industry, ...
San Diego’s Dexcom began sales this week of Stelo, the industry’s first FDA-approved continuous glucose monitor that doesn’t require a prescription. With a two-pack of the biosensor costing just under ...
DexCom (DXCM) faces GLP-1 disruption as it targets non-insulin Type 2 CGM growth. Read here for a detailed invesment analysis ...
Hosted on MSN
New Dexcom CEO wants you to wear a glucose monitor
Supermodel Bambi Northwood-Blyth wears a Dexcom glucose monitor. So does your next-door neighbor with Type 2 diabetes and your fit-fluencer friend. Jake Leach, who took over as Dexcom CEO today, wants ...
Dexcom on Tuesday announced that its new over-the-counter continuous glucose monitor called Stelo has been cleared for use by the FDA. The new CGM is designed for patients with Type 2 diabetes who do ...
No-moat Dexcom DXCM delivered a stellar quarter that reflected ongoing strength in its U.S. launch of G7 and displayed discipline on cost containment. At first blush, we expect to moderately raise our ...
If you are wondering whether DexCom stock still offers value after a choppy few years, this article walks through what the ...
Insulet (PODD) stock and DexCom (DXCM) receive new Buy ratings from Deutsche Bank while Tandem Diabetes Care (TNDM) stock ...
Dexcom shares plunged on disappointing revenue and weak guidance. The stock was down 13% for the year as of Thursday's close. Dexcom makes continuous glucose monitors for patients with diabetes. In ...
EDINBURGH, Scotland & SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced the launch of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results